Corporate - Media & Press - Press Release
Arrayit Founder & VP Todd Martinsky explains Arrayit’s keys to success.
Sunnyvale, CA, January 22, 2003 – On January 22nd, the drug discovery journal PharmaGenomics identified Arrayit as one of only two privately-held biotechnology companies in the United States to shirk a slow economy. The PharmaGenomics article (Vol. 3, number 1) recognized that TeleChem’s continued success in rather tepid economic times “scored major points for the economy’s underdogs.”
Company founder and Executive Vice President Todd Martinsky explained Arrayit’s success in the article. “We have the advantage of a really important application – gene expression. Mapping the human genome was important, but microarrays provide functional information, and that is what researchers really are after. I think were are leading a new project – “The Human Genome Function Project” – and that project starts both with DNA and protein microarrays.”
The PharmaGenomics article further explains Arrayit’s corporate history and how the company showed 492% revenue increase over the 5-year period spanning fiscal years 1997 to 2001.
“We were the first company to create microarray products as consumables and to empower researchers to perform microarray experiments. We are planning to do the same for clinical screening and diagnostics through our diagnostics division,” Martinsky explained.
TeleChem International is a privately owned high-tech company located in the heart of California’s Silicon Valley. Our products and services are provided by three corporate divisions: ArrayIt® Life Sciences Division, Chemicals Division, and a Diagnostics Division. The ArrayIt® Life Sciences Division offers a complete microarray technology platform that empowers >10,000 laboratories to use microarrays for human genome exploration, basic research, drug discovery, and myriad life sciences applications. Nearly every major research institution uses our patented microarray manufacturing technology (U.S. 6,101,946) and supporting products and services. The Chemicals Division provides import and export services and government contract manufacturing in the area of industrial chemicals for plastics, fire control, water treatment, agriculture, industrial and institutional compounding, and green energy. The Diagnostics Division holds key patents in the United States (6,913,879), Singapore (94899), New Zealand (523560), and other countries for its revolutionary “multi-patient” genotyping technology, which allows as many as 100,000 patients to be tested on a single microarray. Arrayit Diagnostics enables genotyping and disease diagnostics by providing testing kits, services, and technology transfer opportunities for disease screening and testing organizations.
Copyright 1993-2018 Arrayit Corporation. All rights reserved.